GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
    American Medical Association (AMA) ; 2023
    In:  JAMA Network Open Vol. 6, No. 1 ( 2023-01-13), p. e2250921-
    Details
    In: JAMA Network Open, American Medical Association (AMA), Vol. 6, No. 1 ( 2023-01-13), p. e2250921-
    Abstract: Individuals who are amyloid-positive with subjective cognitive decline and clinical features increasing the likelihood of preclinical Alzheimer disease (SCD+) are at higher risk of developing dementia. Some individuals with SCD+ undergo amyloid-positron emission tomography (PET) as part of research studies and frequently wish to know their amyloid status; however, the disclosure of a positive amyloid-PET result might have psychological risks. Objective To assess the psychological outcomes of the amyloid-PET result disclosure in individuals with SCD+ and explore which variables are associated with a safer disclosure in individuals who are amyloid positive. Design, Setting, and Participants This prospective, multicenter study was conducted as part of The Amyloid Imaging to Prevent Alzheimer Disease Diagnostic and Patient Management Study (AMYPAD-DPMS) (recruitment period: from April 2018 to October 2020). The setting was 5 European memory clinics, and participants included patients with SCD+ who underwent amyloid-PET. Statistical analysis was performed from July to October 2022. Exposures Disclosure of amyloid-PET result. Main Outcomes and Measures Psychological outcomes were defined as (1) disclosure related distress, assessed using the Impact of Event Scale–Revised (IES-R; scores of at least 33 indicate probable presence of posttraumatic stress disorder [PTSD]); and (2) anxiety and depression, assessed using the Hospital Anxiety and Depression scale (HADS; scores of at least 15 indicate probable presence of severe mood disorder symptoms). Results After disclosure, 27 patients with amyloid-positive SCD+ (median [IQR] age, 70 [66-74] years; gender: 14 men [52%]; median [IQR] education: 15 [13 to 17] years, median [IQR] Mini-Mental State Examination [MMSE] score, 29 [28 to 30] ) had higher median (IQR) IES-R total score (10 [2 to 14] vs 0 [0 to 2] ; P   & amp;lt; .001), IES-R avoidance (0.00 [0.00 to 0.69] vs 0.00 [0.00 to 0.00] ; P   & amp;lt; .001), IES-R intrusions (0.50 [0.13 to 0.75] vs 0.00 [0.00 to 0.25] ; P   & amp;lt; .001), and IES-R hyperarousal (0.33 [0.00 to 0.67] vs 0.00 [0.00 to 0.00] ; P   & amp;lt; .001) scores than the 78 patients who were amyloid-negative (median [IQR], age, 67 [64 to 74] years, 45 men [58%], median [IQR] education: 15 [12 to 17] years, median [IQR] MMSE score: 29 [28 to 30]). There were no observed differences between amyloid-positive and amyloid-negative patients in the median (IQR) HADS Anxiety (–1.0 [–3.0 to 1.8] vs –2.0 [–4.8 to 1.0]; P  = .06) and Depression (–1.0 [–2.0 to 0.0] vs –1.0 [–3.0 to 0.0] ; P  = .46) deltas (score after disclosure – scores at baseline). In patients with amyloid-positive SCD+, despite the small sample size, higher education was associated with lower disclosure-related distress (ρ = –0.43; P  = .02) whereas the presence of study partner was associated with higher disclosure-related distress ( W  = 7.5; P  = .03). No participants with amyloid-positive SCD+ showed probable presence of PTSD or severe anxiety or depression symptoms at follow-up. Conclusions and Relevance The disclosure of a positive amyloid-PET result to patients with SCD+ was associated with a bigger psychological change, yet such change did not reach the threshold for clinical concern.
    Type of Medium: Online Resource
    ISSN: 2574-3805
    URL: Article
    DOI: 10.1001/jamanetworkopen.2022.50921
    Language: English
    Publisher: American Medical Association (AMA)
    Publication Date: 2023
    detail.hit.zdb_id: 2931249-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): Retrospective analyses on the Geneva Memory Clinic cohort : Neuroimaging / differential diagnosis
    Wiley ; 2020
    In:  Alzheimer's & Dementia Vol. 16, No. S5 ( 2020-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 16, No. S5 ( 2020-12)
    Abstract: Advances in the Alzheimer’s disease (AD) field have enhanced awareness on brain health and prevention. This brings an increasing number of adults to ask for help in memory clinics for mild forgetfulness, leading to the increased use of health care resources. Nowadays, about 25% of memory clinics patients complain of cognitive decline in absence of objective deficits (subjective cognitive decline,SCD), and they are expected to increase in the coming years. Some patients with SCD later develop cognitive impairment and dementia, often due to AD, but the majority have psychiatric conditions, physical diseases, polypharmacy, or normal brain ageing. Differentiating these potential causes is often a difficult exercise even for expert physicians. The COSCODE project, funded by Swiss National Science Foundation and led by the Geneva Memory Clinic, aims to identify possible subgroups of SCD and their associated risk of decline. This abstract is focused on the retrospective analyses of SCD patients, to develop and future validate the recruitment criteria and SCD categorization. Methods We included 42 SCD from the Geneva Memory Clinic cohort with the following criteria:(i)Amyloid‐PET;(ii)MRI;(iii)clinical and neuropsychological evaluation;(iv)at least 1 follow‐up planned. To evaluate the representativeness of our sample we assessed the correlation between age, episodic memory and medial temporal lobe atrophy scale; Amyloid SUVr and Episodic memory. Then, a neuropsychologist and a neurologist evaluated the clinical reports in order to identify possible aetiologies of the cognitive complaint. Results In the whole sample (age, mean±SD:71±7years; 54% female; education:16.3±4.1; MMSE:28.8±0.8; 24% A+) age is inversely correlated with episodic memory (Free‐and‐cue‐selective‐reminding‐test, p=0.003) and positively with medial temporal lobe atrophy scale (p=0.017). Amyloid SUVr correlates negatively with episodic memory performance (p 〈 0.05). On the other hands, the clinicians found 3 different aetiologies of the SCD: Comorbidity (stroke, brain injury, cardio‐vascular risk factors, physical disability,...), Psychopathology (depression, anxiety, personality trait); Unknown (apparently, no reason associated to the complaint). The prevalence of the 3 groups is respectively:29%,33%,38%. Conclusions Our SCD sample can be considered representative of a memory clinic population, indeed it’s a very heterogeneous group. The 3 groups categorization will be validated using a data driven approach and studying longitudinal trajectory of each subgroup to better understand their associated risk of decline.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v16.S5
    DOI: 10.1002/alz.045436
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Three‐Objects‐Three‐Places Test: Association with Alzheimer’s Disease Biomarkers
    Wiley ; 2022
    In:  Alzheimer's & Dementia Vol. 18, No. S7 ( 2022-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 18, No. S7 ( 2022-12)
    Abstract: The Three‐Objects‐Three‐Places Psychological Test (3O3P) assesses episodic memory and has been developed to screen for Alzheimer’s Disease (AD). To perform the test, the clinician shows the patient three objects and hides them in three separate locations. The patient is later asked what the objects and hiding places were, and which object was hidden where, producing a score out of 9. The aim of this study was to investigate if 3O3P scores were associated with common AD biomarkers to test its potential efficacy in detection of AD pathology, and how these associations compared with other common AD neuropsychological tests. Method 166 patients from the Geneva Memory Centre cohort (106 MCI, 19 dementia, and 41 unimpaired) who underwent amyloid‐PET, tau‐PET, MRI, as well as clinical and neuropsychological assessments, were included. The biomarkers tested included amyloid (A) and tau (T) load, and cortical thickness (N). Associations between these biomarkers and 3O3P scores, MMSE and delayed total recall scores (DTR; extracted from the 16‐item Free and Cued Recall) were tested. The associations between biomarkers and test scores were investigated using linear regression. Result Mean patient age was 71 years, 52% were female, and mean years of education was 14. When controlling for age and education, 3O3P scores were negatively associated with amyloid (b = ‐0.02, p 〈 0.001), tau load (b = ‐4.14, p 〈 0.001), and positively with cortical thickness (b = 7.21, p 〈 0.001). Similar trends were seen between these biomarkers and MMSE (A: b = ‐0.02; T: b = ‐5.21; N: b = 8.18, p 〈 0.001) and DTR scores (A: b = ‐0.03; T: b = ‐5.28; N: b = 10.2, p 〈 0.001). Conclusion These preliminary findings indicate that 3O3P scores correlate significantly with the AD biomarkers tested, as do MMSE and DTR scores. However, the 3O3P test carries advantages, such as its short duration, easy administration, and not requiring the examiner to purchase equipment or score sheets. Further analysis is needed to clarify the relationship between 3O3P scores and AD biomarkers.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v18.S7
    DOI: 10.1002/alz.065467
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Inverse relationship between education and amyloid burden in individuals with subjective cognitive decline plus and mild cognitive impairment
    Wiley ; 2023
    In:  Alzheimer's & Dementia Vol. 19, No. S3 ( 2023-06)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 19, No. S3 ( 2023-06)
    Abstract: Higher educated patients with MCI can tolerate more neuropathology than lower educated patients with similar clinical impairment. It is not known whether this observation also accounts for potential preclinical stages of AD, namely subjective cognitive decline plus (SCD+). Method Data of 197 SCD+ individuals, 227 MCI and 157 AD patients were included, which were collected as part of the AMYPAD‐DPMS cohort (https://amypad.eu/). First, median education in years was computed across the AD‐spectrum groups for each of the 8 European sites. Next, using a median split, the SCD+, MCI and AD cohort were separately categorized into a higher and lower educated group, excluding subjects with median education. Afterwards, the higher and lower educated AD‐spectrum groups were matched for age, sex and cognitive function (MMSE) using propensity score matching in R, leading to the following sample (low/high education): 54/54 SCD+, 70/81 MCI and 56/65 AD patients. Global amyloid load was compared between education groups using Centiloid (CL) information derived from Flutemetamol and Florbetaben PET scans. To confirm the results of the stringent group comparison, partial correlations between years of education and CL values correcting for age, sex and tracer type were performed for each AD‐spectrum group. All analyses were conducted in SPSS 28 and significance level was set to p 〈 .05. Result Higher educated SCD+ subjects presented significantly (p 〈 . 001) lower CL values (M(CL) = 16.48) than lower educated SCD+ subjects (M(CL) = 32.17), whereas the opposite effect (p 〈 .046) was observed in the MCI cohort with higher educated MCI patients presenting greater CL values (M(CL) = 57.08) compared to the lower educated MCI group (M(CL) = 41.74). No difference was found in the AD group. Results were further confirmed by the correlation approach across the unmatched sample yielding a negative association between years of education and CL values in the SCD+ group (r = ‐.159, p = .027) and a positive association in the MCI group (r = .153, p = .022). Conclusion These results indicate that sensitivity to early amyloid accumulation may possibly increase with higher education in potential preclinical stages of AD, whereas in clinical stages of AD higher education may support compensatory mechanisms against amyloid burden.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v19.S3
    DOI: 10.1002/alz.064097
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
    BMJ ; 2023
    In:  Journal of Neurology, Neurosurgery & Psychiatry Vol. 94, No. 6 ( 2023-06), p. 420-427
    Details
    In: Journal of Neurology, Neurosurgery & Psychiatry, BMJ, Vol. 94, No. 6 ( 2023-06), p. 420-427
    Abstract: The key Alzheimer’s disease (AD) biomarkers are traditionally measured with techniques/exams that are either expensive (amyloid-positron emission tomography (PET) and tau-PET), invasive (cerebrospinal fluid Aβ 42 and p-tau 181 ), or poorly specific (atrophy on MRI and hypometabolism on fluorodeoxyglucose-PET). Recently developed plasma biomarkers could significantly enhance the efficiency of the diagnostic pathway in memory clinics and improve patient care. This study aimed to: (1) confirm the correlations between plasma and traditional AD biomarkers, (2) assess the diagnostic accuracy of plasma biomarkers as compared with traditional biomarkers, and (3) estimate the proportion of traditional exams potentially saved thanks to the use of plasma biomarkers. Methods Participants were 200 patients with plasma biomarkers and at least one traditional biomarker collected within 12 months. Results Overall, plasma biomarkers significantly correlated with biomarkers assessed through traditional techniques: up to r =0.50 (p 〈 0.001) among amyloid, r =0.43 (p=0.002) among tau, and r =−0.23 (p=0.001) among neurodegeneration biomarkers. Moreover, plasma biomarkers showed high accuracy in discriminating the biomarker status (normal or abnormal) determined by using traditional biomarkers: up to area under the curve (AUC)=0.87 for amyloid, AUC=0.82 for tau, and AUC=0.63 for neurodegeneration status. The use of plasma as a gateway to traditional biomarkers using cohort-specific thresholds (with 95% sensitivity and 95% specificity) could save up to 49% of amyloid, 38% of tau, and 16% of neurodegeneration biomarkers. Conclusion The implementation of plasma biomarkers could save a remarkable proportion of more expensive traditional exams, making the diagnostic workup more cost-effective and improving patient care.
    Type of Medium: Online Resource
    ISSN: 0022-3050 , 1468-330X
    URL: Article
    DOI: 10.1136/jnnp-2022-330619
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2023
    detail.hit.zdb_id: 1480429-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Impact of the disclosure of amyloid‐PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS) : Neuroimaging / Normal brain aging
    Wiley ; 2020
    In:  Alzheimer's & Dementia Vol. 16, No. S5 ( 2020-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 16, No. S5 ( 2020-12)
    Abstract: Amyloid‐PET is increasingly used for diagnostic purposes in patients with cognitive impairment due to suspected Alzheimer’s disease. However, cognitively unimpaired individuals are frequently included in research studies involving amyloid‐PET scan. Even if amyloid‐PET is not clinically recommended in these cases, these patients often want to know their amyloid status, a strong risk factor for incident dementia. Currently, evidence on the impact of the disclosure of amyloid‐PET results on patients’ psychological well‐being is scanty. The aim of this sub‐study is to assess how a positive amyloid‐PET result affects the psychological well‐being of patients with subjective cognitive decline plus (SCD+) enrolled in a prospective study on the diagnostic utility of amyloid PET (AMYPAD‐DPMS). Method The impact of the disclosure of amyloid‐PET results on patient’s psychological well‐being was investigated using the Impact of Event Scale–Revised (IES‐R). IES‐R is used to detect potential changes from the current time point and a previous time point preceding up to 7 days an event (the amyloid‐PET result disclosure in this case). IES‐R was administered 1‐3 days post‐disclosure, and consists of one total score (0‐88) and three sub‐scores (0‐4): avoidance (avoidance of thoughts, feelings, memories or situations), intrusions (intrusive memories, thoughts, or feelings causing distress), and hyperarousal (hypervigilance, feeling watchful and on guard, difficulty concentrating). IES‐R total score between 12‐32: symptoms of post‐traumatic stress, patient monitoring is required; ≥33: probable presence of a post‐traumatic stress disorder. Result So far, 36 SCD+ participants of AMYPAD‐DPMS, who received their amyloid‐PET results, have accepted to participate in this sub‐study. Amyloid‐positive patients (n=9) had higher IES‐R total score (median=10, lower‐upper quartiles=1‐14) than amyloid‐negatives (1, 0‐6), albeit at trend level ( p =0.052). We also observed higher avoidance scores in amyloid‐positives compared to amyloid‐negatives (0, 0.00‐0.62 vs. 0, 0.00‐0.00, p =0.004), but no differences in the other two sub‐scores ( p 〉 0.05). Conclusion These preliminary data on 36 participants suggests that the disclosure of positive amyloid scan to an SCD+ patient is associated with the avoidance of thoughts and memories of the news. Future analyses will address additional outcome measures (e.g. post‐disclosure anxiety and depression) and factors associated with a milder psychological impact in amyloid‐positive patients.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v16.S5
    DOI: 10.1002/alz.040952
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    The use of amyloid‐PET in memory clinic patients: AMYPAD Diagnostic and Patient Management Study
    Wiley ; 2022
    In:  Alzheimer's & Dementia Vol. 18, No. S5 ( 2022-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 18, No. S5 ( 2022-12)
    Abstract: Amyloid‐PET allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer’s disease. However, this technique is currently not or incompletely reimbursed due to lack of randomized controlled studies demonstrating a clinical impact. Method AMYPAD‐DPMS is a prospective, multicenter, randomized controlled study. Patients with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI) or dementia from 8 European memory clinics were randomized into three study arms: ARM1, amyloid‐PET performed early in the diagnostic workup (within 1 month); ARM2, late in the diagnostic workup (after 8±2 months); or ARM3, if and when the managing physician chose to. The primary endpoint was the proportional difference in ARM1 and ARM2 participants in receiving an etiological diagnosis with very high diagnostic confidence (i.e. ≥ 90%) within 3 months. Secondary endpoints included changes in diagnosis and treatment plan. Result Participants were recruited from April 16th, 2018, to October 30th, 2020. There were 272 participants in ARM1, 260 ARM2, and 261 ARM3 that underwent both baseline and 3‐month visit. 88% of ARM3 participants underwent amyloid‐PET within 3 months, and the average time from baseline to prescribe amyloid‐PET was 46 (IQR=58) days. After 3 months, 40% (109/272) of ARM1 participants and 37% (97/261) of ARM3 had a diagnosis with very high confidence vs 11% (30/260) in ARM2 (p 〈 0.001). This was consistent across clinical stages (SCD+: 30%, 22%, and 6%, p 〈 0.05; MCI: 42%, 39%, and 9%, p 〈 0.05; dementia: 49%, 49%, and 20%, p 〈 0.05). Changes in diagnosis were more frequent in ARM1 (44%) versus ARM3 (29%, p=0.001) and ARM2 (11%, p 〈 0.001), and in ARM3 versus ARM2 (p 〈 0.001). In participants for whom an etiological diagnosis of AD or non‐AD was confirmed after 3 months, changes in diagnostic confidence were greater in ARM1 (AD: +14%; non‐AD: +12%) and ARM3 (+11%; +10%) vs ARM2 (+1%, +1%; p 〈 0.05). Conclusion An amyloid‐PET performed in the early phases of a diagnostic workup is associated with a greater proportion of etiological diagnoses with very high confidence and more frequent changes in diagnosis and higher diagnostic confidence after 3 months. This evidence supports the implementation of this technique early in the diagnostic workup.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v18.S5
    DOI: 10.1002/alz.064648
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease
    Springer Science and Business Media LLC ; 2020
    In:  European Journal of Nuclear Medicine and Molecular Imaging Vol. 47, No. 2 ( 2020-2), p. 270-280
    Details
    In: European Journal of Nuclear Medicine and Molecular Imaging, Springer Science and Business Media LLC, Vol. 47, No. 2 ( 2020-2), p. 270-280
    Type of Medium: Online Resource
    ISSN: 1619-7070 , 1619-7089
    URL: Article
    DOI: 10.1007/s00259-019-04466-6
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2020
    detail.hit.zdb_id: 2098375-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants : Neuroimaging / differential diagnosis
    Wiley ; 2020
    In:  Alzheimer's & Dementia Vol. 16, No. S5 ( 2020-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 16, No. S5 ( 2020-12)
    Abstract: AMYPAD‐DPMS is the largest European, multicenter, prospective and randomized study assessing clinical utility and cost‐effectiveness of amyloid‐PET in a controlled but realistic clinical setting. In the present abstract we report preliminary results on the baseline features of the first study participants. Method A total of 900 participants (300 with subjective cognitive decline plus [SCD+], 300 with mild cognitive impairment [MCI] , and 300 with dementia) will be enrolled and randomized into 3 study arms: ARM‐1, amyloid‐PET performed early in the diagnostic workup; ARM‐2, amyloid‐PET performed late in the diagnostic work‐up; and ARM‐3, amyloid‐PET performed if and when the physician chooses to. Result As of January 23 rd 2020, 617 participants (154 SCD+, 303 MCI, and 160 dementia) have been enrolled from 8 centers. Baseline features are reported in Table 1. SCD+ participants are younger than MCI ( p =0.006) and dementia ( p 〈 0.001) participants. SCD+ are more highly educated than MCI and dementia ( p 〈 0.001), and MCI are more highly educated that dementia ( p =0.008). As expected, worse global cognition is observed in dementia ( p 〈 0.001) compared to MCI and SCD+, and in MCI compared to SCD+ ( p 〈 0.001). Among those who already underwent amyloid‐PET, 34% (30/88) of SCD+, 58% (90/155) of MCI, and 74% (60/81) of dementia patients were amyloid‐positive based on visual PET scan assessment. Conclusion The socio‐demographic and cognitive features of the first 68% of AMYPAD‐DPMS participants are as expected for a memory clinic population, confirming the inclusion/exclusion criteria resulted in a representative sample. These results support the generalizability of the final study results. The end of participants’ enrolment is expected by mid‐2020.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v16.S5
    DOI: 10.1002/alz.042628
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Quantitative amyloid‐PET measures in a memory clinic population
    Wiley ; 2022
    In:  Alzheimer's & Dementia Vol. 18, No. S6 ( 2022-12)
    Details
    In: Alzheimer's & Dementia, Wiley, Vol. 18, No. S6 ( 2022-12)
    Abstract: In clinical practice, visual assessment of amyloid‐PET images results in a binary classification (negative or positive) of amyloid status. While this approach has shown high clinical utility, the expected approval of disease‐modifying treatments warrants the need for objective amyloid burden quantification, to further support a high‐confidence diagnosis of Alzheimer’s disease (AD) and treatment decisions. We investigated two widely available quantification methods, i.e. Centiloid (CL) and z‐scores to optimize clinical use of amyloid‐PET. Methods Patients with subjective cognitive decline plus (SCD+; N =220), mild cognitive impairment (MCI; N =293) or dementia ( N =216) enrolled in the AMYPAD‐DPMS that have undergone amyloid‐PET imaging and passed quality control were included in the study. Acquired static (i.e. 90‐110 min. post‐injection) [ 18 F]flutemetamol ( N =380) or [ 18 F]florbetaben ( N =349) PET images were processed using GE Healthcare’s AMYPYPE PET‐only pipeline, providing global CL, z‐scores, and z‐scores for 7 cortical ROIs. Local readers provided visual read (VR) status and regional assessments. Results Demographics are shown in Table 1 . In total, 364 (49.9%) patients were assessed as amyloid VR‐positive and showed significantly higher CL ( U =3954, p 〈 0.001) and global z‐score ( U =4197, p 〈 0.001) values across clinical stages compared to VR‐negative patients ( Figure 1A ). The proportion of VR‐positive patients increased with clinical stage (SCD+: 30.0%, MCI: 48.8%, dementia: 71.8%) and global amyloid burden (CL: H =24.97, p 〈 0.001; z‐score: H =24.43, p 〈 0.001) was also associated with disease severity ( Figure 1B ). VR‐positive patients with a primary etiological diagnosis of AD showed higher overall higher amyloid burden (CL: H =6.93, p =0.008; z‐score: H =5.54, p =0.019) and specifically in the pre‐frontal cortex ( H =8.18, p =0.004) compared to patients with a non‐AD primary etiological diagnosis, though percentage of frontal VR‐positivity was highly similar between groups (AD: 97.2% vs. non‐AD: 96.6%). Global CL and z‐scores were highly correlated ( ρ =.987, p 〈 0.001), by a factor of 10 ( Figure 1C ). Conclusion Our results demonstrate high agreement between CL and z‐scoring quantitative measures in a clinical population. While initial results do not indicate differences in patterns of regional positivity between AD and non‐AD subjects, differences in global amyloid burden seem to be driven by known AD‐related early accumulating regions. Additional analyses comparing other etiological groups will be presented at the conference.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    URL: Article
    DOI: 10.1002/alz.v18.S6
    DOI: 10.1002/alz.062326
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...